Intact Investment Management Inc. Makes New $420,000 Investment in Moderna, Inc. (NASDAQ:MRNA)

Intact Investment Management Inc. acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, Holdings Channel.com reports. The fund acquired 10,100 shares of the company’s stock, valued at approximately $420,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. LBP AM SA boosted its stake in Moderna by 4,643.2% during the fourth quarter. LBP AM SA now owns 184,606 shares of the company’s stock worth $7,676,000 after buying an additional 180,714 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after purchasing an additional 345 shares during the period. Vestcor Inc boosted its stake in shares of Moderna by 15.0% during the fourth quarter. Vestcor Inc now owns 6,569 shares of the company’s stock valued at $273,000 after purchasing an additional 855 shares during the period. Rakuten Securities Inc. boosted its stake in shares of Moderna by 696.9% during the fourth quarter. Rakuten Securities Inc. now owns 7,499 shares of the company’s stock valued at $312,000 after purchasing an additional 6,558 shares during the period. Finally, Avantax Advisory Services Inc. purchased a new stake in shares of Moderna during the fourth quarter valued at $483,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Up 0.9 %

MRNA opened at $34.62 on Friday. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a market cap of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86. The firm’s 50-day moving average price is $35.94 and its 200-day moving average price is $47.37.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MRNA. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Morgan Stanley lowered their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. UBS Group lowered their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.